[1]Patent:WO2008/47082,2008,A2.Locationinpatent:Page/Pagecolumn23
[2]Patent:CN106928149,2017,A.Locationinpatent:Paragraph0008;0047-0049
[3]Patent:CN105985294,2016,A.Locationinpatent:Paragraph0051;0052;0053
[1]Patent:CN105820126,2016,A.Locationinpatent:Paragraph0057;0058
[2]Patent:CN108129397,2018,A.Locationinpatent:Paragraph0044;0049;0077
[3]Patent:CN110078671,2019,A.Locationinpatent:Paragraph0030-0031
[4]Patent:WO2019/186135,2019,A1.Locationinpatent:Page/Pagecolumn62-63;65
[5]JournalofMedicinalChemistry,2008,vol.51,p.6581-6591
[6]Patent:WO2008/47082,2008,A2.Locationinpatent:Page/Pagecolumn24
[7]Patent:WO2009/50469,2009,A1.Locationinpatent:Page/Pagecolumn12;13
[1]CurrentPatentAssignee:HEFEICHUANGXINMEDICALTECH-CN109535082,2019,ALocationinpatent:Paragraph0058;0064;0070;0076;0083;0084;0085;0093
[2]CurrentPatentAssignee:JARIPHARMACEUTICAL-CN112047890,2020,ALocationinpatent:Paragraph0038-0041
[3]CurrentPatentAssignee:ZILUOPHARMACEUTICALCOLTD-CN114249695,2022,ALocationinpatent:Paragraph0020;0063-0066
[4]CurrentPatentAssignee:BEIJINGMESOCHEMTECH-CN113234024,2021,ALocationinpatent:Paragraph0020;0026
[5]CurrentPatentAssignee:ASTRAZENECAPLC-WO2008/47082,2008,A2Locationinpatent:Page/Pagecolumn25-26
[6]CurrentPatentAssignee:GUANGZHOURENHENGPHARMACEUTICALTECH-CN106905243,2017,ALocationinpatent:Paragraph0066;0067
[7]CurrentPatentAssignee:JILINSIHUANPHARMA;JILINHUIKANGPHARMACEUTICAL;BEIJINGSIHUANPHARM-CN114075159,2022,ALocationinpatent:Paragraph0059;0107-0116;0137-0158
[8]CurrentPatentAssignee:JILINHUIKANGPHARMACEUTICAL;JILINSIHUANPHARMA;BEIJINGSIHUANPHARM-CN114075143,2022,ALocationinpatent:Paragraph0153;0158-0159;0164-0165;0169-0170;0174
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,p.6142-6147
[2]Patent:CN108586355,2018,A.Locationinpatent:Paragraph0043;0047
[3]Patent:CN108191769,2018,A.Locationinpatent:Paragraph0047-0055
[4]Journaloflabelledcompoundsandradiopharmaceuticals,2012,vol.55,p.411-418
[5]OrganicLetters,2019,vol.21,p.5775-5778
[1]Modvig,Amalie;Andersen,ThomasL.;Taaning,RolfH.;Lindhardt,AndersT.;Skrydstrup,Troels[JournalofOrganicChemistry,2014,vol.79,#12,p.5861-5868]
[2]Flinker,Mathias;Yin,Hongfei;Juhl,RenéW.;Eikeland,EspenZ.;Overgaard,Jacob;Nielsen,DennisU.;Skrydstrup,Troels[AngewandteChemie-InternationalEdition,2017,vol.56,#50,p.15910-15915][Angew.Chem.,2017,vol.56,#50,p.15910-15915,6]
Title: Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.
Journal: Nature genetics 20180801
Title: An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Journal: BMC cancer 20160101
Title: 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53.
Journal: Oncotarget 20151222
Title: PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Journal: Molecular cancer therapeutics 20151201
Title: DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Journal: The New England journal of medicine 20151029
Title: Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Journal: Journal of medicinal chemistry 20150910
Title: Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20150401
Title: Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.
Journal: Cell metabolism 20140603
Title: Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
Journal: Nature reviews. Drug discovery 20140601
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Journal: Cancer discovery 20130101
Title: Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Journal: Cancer research 20121101
Title: Olaparib, PARP1 inhibitor in ovarian cancer.
Journal: Expert opinion on investigational drugs 20121001
Title: Clinical trials and future potential of targeted therapy for ovarian cancer.
Journal: International journal of clinical oncology 20121001
Title: Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Journal: EMBO molecular medicine 20121001
Title: [Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20121001
Title: Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Journal: Current opinion in oncology 20120901
Title: Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Journal: Breast cancer research and treatment 20120901
Title: Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Journal: Cancer discovery 20120901
Title: Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Journal: Investigational new drugs 20120801
Title: Neoadjuvant treatments for triple-negative breast cancer (TNBC).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120801
Title: Olaparib in platinum-sensitive ovarian cancer.
Journal: The New England journal of medicine 20120712
Title: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
Journal: Breast cancer research and treatment 20120701
Title: BAP1 loss defines a new class of renal cell carcinoma.
Journal: Nature genetics 20120701
Title: Current and emerging targeted therapies for metastatic breast cancer.
Journal: Cancer 20120615
Title: Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
Journal: Hepatology (Baltimore, Md.) 20120601
Title: Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Journal: EMBO molecular medicine 20120601
Title: A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120415
Title: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Journal: The New England journal of medicine 20120412
Title: PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Journal: Cancer research 20120401
Title: A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Journal: The oncologist 20120401
Title: [PARP inhibitors and breast cancer: update and perspectives].
Journal: Bulletin du cancer 20120401
Title: Drug candidates derailed in case of mistaken identity.
Journal: Nature 20120328
Title: Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
Title: A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
Journal: Cancer science 20120301
Title: Synthetic lethality of cohesins with PARPs and replication fork mediators.
Journal: PLoS genetics 20120301
Title: Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.
Journal: Neoplasia (New York, N.Y.) 20120301
Title: Present status and problems on molecular targeted therapy of cancer.
Journal: Cancer research and treatment : official journal of Korean Cancer Association 20120301
Title: Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Journal: Nature biotechnology 20120219
Title: Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.
Journal: Molecular cell 20120210
Title: Structural basis of selective inhibition of human tankyrases.
Journal: Journal of medicinal chemistry 20120209
Title: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201
Title: Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Journal: British journal of cancer 20120131
Title: Basal breast cancer: a complex and deadly molecular subtype.
Journal: Current molecular medicine 20120101
Title: Ovarian cancer: opportunity for targeted therapy.
Journal: Journal of oncology 20120101
Title: BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
Journal: PloS one 20120101
Title: Molecular basis of triple negative breast cancer and implications for therapy.
Journal: International journal of breast cancer 20120101
Title: Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.
Journal: International journal of breast cancer 20120101
Title: Therapeutic strategies in epithelial ovarian cancer.
Journal: Journal of experimental & clinical cancer research : CR 20120101
Title: Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.
Journal: PloS one 20120101
Title: Major clinical research advances in gynecologic cancer in 2011.
Journal: Journal of gynecologic oncology 20120101
Title: Advances in using PARP inhibitors to treat cancer.
Journal: BMC medicine 20120101
Title: Novel binding mode of a potent and selective tankyrase inhibitor.
Journal: PloS one 20120101
Title: Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.
Journal: Journal of oncology 20120101
Title: Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene.
Journal: PloS one 20120101
Title: Brain metastases from endometrial carcinoma.
Journal: ISRN oncology 20120101
Title: The combination of olaparib and camptothecin for effective radiosensitization.
Journal: Radiation oncology (London, England) 20120101
Title: Combination drug delivery approaches in metastatic breast cancer.
Journal: Journal of drug delivery 20120101
Title: Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.
Journal: PloS one 20120101
Title: The first European interdisciplinary ewing sarcoma research summit.
Journal: Frontiers in oncology 20120101
Title: Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.
Journal: Anemia 20120101
Title: Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.
Journal: PloS one 20120101
Title: Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Journal: Cell cycle (Georgetown, Tex.) 20111215
Title: The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Journal: Current drug targets 20111201
Title: Update on PARP1 inhibitors in ovarian cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20111201
Title: PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Journal: Oncotarget 20111201
Title: Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Journal: Nuclear medicine communications 20111101
Title: BRCA1 and BRCA2 mutations and breast cancer.
Journal: Discovery medicine 20111101
Title: Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?
Journal: Journal of clinical pathology 20111001
Title: Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Journal: Molecular cancer therapeutics 20111001
Title: PARP inhibitors--current status and the walk towards early breast cancer.
Journal: Breast (Edinburgh, Scotland) 20111001
Title: Functional characterization of EMSY gene amplification in human cancers.
Journal: The Journal of pathology 20110901
Title: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Journal: The Lancet. Oncology 20110901
Title: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110801
Title: An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110701
Title: Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701
Title: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Journal: The Journal of clinical investigation 20110701
Title: Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Journal: Nature medicine 20110701
Title: PARP inhibitors: its role in treatment of cancer.
Journal: Chinese journal of cancer 20110701
Title: The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.
Journal: PLoS genetics 20110701
Title: Epistatic relationships in the BRCA1-BRCA2 pathway.
Journal: PLoS genetics 20110701
Title: Novel agents and future directions for refractory breast cancer.
Journal: Seminars in oncology 20110601
Title: Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
Journal: Nature reviews. Clinical oncology 20110501
Title: 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).
Journal: Journal of medicinal chemistry 20110414
Title: MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.
Journal: The Journal of biological chemistry 20110408
Title: A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Journal: British journal of cancer 20110301
Title: Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method.
Journal: Angewandte Chemie (International ed. in English) 20110218
Title: Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110215
Title: Characteristics of triple-negative breast cancer.
Journal: Journal of cancer research and clinical oncology 20110201
Title: 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
Journal: Current opinion in obstetrics & gynecology 20110201
Title: Triple negative breast cancer: unmet medical needs.
Journal: Breast cancer research and treatment 20110201
Title: Immunophenotypic predictive profiling of BRCA1-associated breast cancer.
Journal: Virchows Archiv : an international journal of pathology 20110101
Title: Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks.
Journal: Genome integrity 20110101
Title: Breast cancer genome heterogeneity: a challenge to personalised medicine?
Journal: Breast cancer research : BCR 20110101
Title: PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Journal: Acta clinica Belgica 20110101
Title: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Journal: Journal of hematology & oncology 20110101
Title: BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101
Title: Concordant and opposite roles of DNA-PK and the 'facilitator of chromatin transcription' (FACT) in DNA repair, apoptosis and necrosis after cisplatin.
Journal: Molecular cancer 20110101
Title: Targeted therapy in breast cancer: what's new?
Journal: Swiss medical weekly 20110101
Title: Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
Journal: Cancer management and research 20110101
Title: Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Journal: BMC pharmacology 20110101
Title: Rare variants in the ATM gene and risk of breast cancer.
Journal: Breast cancer research : BCR 20110101
Title: Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
Journal: PloS one 20110101
Title: Drug therapy for hereditary cancers.
Journal: Hereditary cancer in clinical practice 20110101
Title: Management options in triple-negative breast cancer.
Journal: Breast cancer : basic and clinical research 20110101
Title: Genetic dissection of PARylation in the filamentous fungus Neurospora crassa.
Journal: Methods in molecular biology (Clifton, N.J.) 20110101
Title: Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Journal: Breast cancer research : BCR 20110101
Title: Platinum resistance in breast and ovarian cancer cell lines.
Journal: Journal of experimental & clinical cancer research : CR 20110101
Title: MicroRNAs associated with metastatic prostate cancer.
Journal: PloS one 20110101
Title: A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.
Journal: BMC medical genetics 20110101
Title: Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
Journal: BMC medical genomics 20110101
Title: Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.
Journal: PloS one 20110101
Title: Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Journal: PloS one 20110101
Title: Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.
Journal: International journal of surgical oncology 20110101
Title: Triple-negative breast cancer: adjuvant therapeutic options.
Journal: Chemotherapy research and practice 20110101
Title: Multidrug resistance in breast cancer: from in vitro models to clinical studies.
Journal: International journal of breast cancer 20110101
Title: Therapeutic targeting of cancer stem cells.
Journal: Frontiers in oncology 20110101
Title: BRCA mutations in the management of breast cancer: the state of the art.
Journal: Nature reviews. Clinical oncology 20101201
Title: [PARP inhibitors to treat triple negative breast cancer].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20101201
Title: The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Journal: Blood 20101125
Title: Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Journal: British journal of cancer 20101109
Title: Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Journal: Cellular and molecular life sciences : CMLS 20101101
Title: Molecule of the month. Olaparib.
Journal: Drug news & perspectives 20101101
Title: Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
Journal: Nature structural & molecular biology 20101001
Title: Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations.
Journal: Nature reviews. Clinical oncology 20101001
Title: Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.
Journal: PLoS genetics 20101001
Title: PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Journal: Current opinion in oncology 20100901
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20100901
Title: Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.
Journal: Journal of the National Cancer Institute 20100804
Title: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Journal: Lancet (London, England) 20100724
Title: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Journal: Lancet (London, England) 20100724
Title: [Treatment with oral agents for breast cancer].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20100701
Title: Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery.
Journal: IDrugs : the investigational drugs journal 20100601
Title: Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Journal: Molecular cancer therapeutics 20100601
Title: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100520
Title: Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.
Journal: Yonsei medical journal 20100501
Title: Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Journal: Cancer research 20100215
Title: ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Journal: Molecular cancer therapeutics 20100201
Title: A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100101
Title: The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
Journal: Journal of oncology 20100101
Title: A current review of targeted therapeutics for ovarian cancer.
Journal: Journal of oncology 20100101
Title: Targeted therapies in epithelial ovarian cancer.
Journal: Journal of oncology 20100101
Title: Targeted therapy in ovarian cancer.
Journal: Journal of oncology 20100101
Title: Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Journal: Breast cancer research : BCR 20100101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20100101
Title: Biology-driven cancer drug development: back to the future.
Journal: BMC biology 20100101
Title: Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
Journal: Cancer journal (Sudbury, Mass.) 20100101
Title: Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
Journal: Breast cancer research : BCR 20100101
Title: Does race affect outcomes in triple negative breast cancer?
Journal: Breast cancer : basic and clinical research 20100101
Title: Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.
Journal: BMC cancer 20100101
Title: PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
Journal: F1000 biology reports 20100101
Title: Treatment options for patients with triple-negative breast cancer.
Journal: Journal of hematology & oncology 20100101
Title: Present and future evolution of advanced breast cancer therapy.
Journal: Breast cancer research : BCR 20100101
Title: Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.
Journal: Breast cancer research : BCR 20100101
Title: Triple-negative breast cancer.
Journal: Breast cancer research : BCR 20100101
Title: Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.
Journal: Breast cancer research : BCR 20100101
Title: Are current development programs realising the full potential of new agents?
Journal: Breast cancer research : BCR 20100101
Title: New developments in treatment of ovarian carcinoma: focus on trabectedin.
Journal: Cancer management and research 20100101
Title: Preclinical mouse models for BRCA1-associated breast cancer.
Journal: British journal of cancer 20091117
Title: Converting cancer mutations into therapeutic opportunities.
Journal: EMBO molecular medicine 20090901
Title: Triple-negative breast cancer: novel therapies and new directions.
Journal: Maturitas 20090820
Title: Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
Journal: Cancer cell 20090804
Title: Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
Journal: Molecular cancer therapeutics 20090801
Title: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Journal: The New England journal of medicine 20090709
Title: Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Journal: Cancer research 20090501
Title: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Journal: Breast cancer research : BCR 20090101
Title: BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
Journal: Journal of ovarian research 20090101
Title: Synthetic lethality: a framework for the development of wiser cancer therapeutics.
Journal: Genome medicine 20090101
Title: PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Journal: Breast cancer research : BCR 20090101
Title: Are current drug development programmes realising the full potential of new agents? The scenario.
Journal: Breast cancer research : BCR 20090101
Title: Tailored targeted therapy for all: a realistic and worthwhile objective?
Journal: Breast cancer research : BCR 20090101
Title: Recent advances in managing triple-negative breast cancers.
Journal: F1000 medicine reports 20090101
Title: Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.
Journal: International journal of radiation oncology, biology, physics 20081115
Title: High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20081104
Title: 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Journal: Journal of medicinal chemistry 20081023
Title: A FlashPlate assay for the identification of PARP-1 inhibitors.
Journal: Journal of biomolecular screening 20030601
Title: Menear KA, et al. 4--(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91
Title: Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Mol Cancer Ther. 2011 Oct;10(10):1949-58.
Title: Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci. 2016 Feb 24;17(3):272.
Title: Bian X, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018 Jan 18;37(3):341-351.
